Drugs / eneboparatide
eneboparatide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05239221 | Sep 2020 → Aug 2022 | hypoparathyroidism | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT05778071 | Jun 2023 → Nov 2024 overdue | hypoparathyroidism | Alexion Pharmaceuticals, Inc. | Active not recruiting | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-05-12 | AstraZeneca | Results Eneboparatide normalised serum calcium and achieved independence from active vitamin D and oral calcium supplements in 31.1% of adults with hypoparathyroidism at week 24 in CALYPSO Phase III trial astrazeneca.com ↗ |
| 2025-03-17 | AstraZeneca | Results Eneboparatide met primary endpoint of normalising serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO Phase III trial astrazeneca.com ↗
High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical significance in adults with chronic hypoparathyroidism (HypoPT) at 24 weeks, compared to placebo. |
All press releases naming this drug 2 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | eneboparatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05778071 ↗ |
| Known as | AZP-3601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05239221 ↗ |
| Known as | Eneboparatida | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095311 ↗ |
| Action | Activate | “Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist.” PMID 40423237 ↗ Jun 2025 |
| Modality | Protein / enzyme biologic | — CHEMBL5095311 ↗ |
| Route | Subcutaneous | “subcutaneous (sc) administration once daily” NCT05239221 ↗ |